
Brian I. Rini, MD, professor of medicine at the Cleveland Clinic, discusses how data should be looked at between 2 combinations for the treatment of renal cell carcinoma. He says atezolizumab plus bevacizumab will never be compared head to head with ipilimumab plus nivolumab.





























